Osteoboost Health Launches Wearable Device for Low Bone Density in the U.S.

Osteoboost Health has announced nationwide availability of Osteoboost, a wearable prescription device designed to support individuals with low bone density. Approved by the FDA via the de novo pathway and recognized as a breakthrough device, Osteoboost uses targeted vibration therapy to help slow bone loss in the hips and spine, areas vulnerable to osteoporotic fractures.

Clinical validation from a double-blind, placebo-controlled trial at the University of Nebraska Medical Center showed that postmenopausal women with osteopenia using the device three times weekly experienced up to 85% reduction in spinal bone density loss and a 55% reduction at the hip.

The lightweight belt delivers 30-minute daily sessions and can be worn during regular activities. To enhance access, Osteoboost Health has partnered with Beluga Health for online prescription consultations and previously acquired Wellen, a digital platform focused on exercise and fall prevention for women with low bone density.

19-05-2025